

In the Claims:

2. (Currently amended) A method for treating donor cells to ameliorate graft versus host disease in a recipient patient comprising:

- a) removing peripheral blood mononuclear cells (PBMC) from a donor;
- b) treating said PBMC with a suppressive-inducing composition comprising TGF-β, IL-2, and a T cell activator for a time sufficient to induce T cell tolerance in said patient; and
- c) introducing said treated PBMC to said patient.

[Claims 3-4 (Cancelled)]

[5. (Withdrawn)]

6. A method according to claim 2 wherein said method further comprises adding said cells to donor stem cells prior to introduction into said patient.

[Claims 7-8 (Withdrawn)]

10. (Currently amended) A method for treating donor cells to ameliorate graft versus host disease in a recipient patient comprising:

- a) removing peripheral blood mononuclear cells (PBMC) from a donor;
- b) treating said PBMC with a suppressive-inducing composition comprising TGF-β, IL-2, and a T cell activator for a time sufficient to generate suppressor cells; and
- c) introducing said suppressor cells to said patient.

[Claims 11-13 (Cancelled)]

[14. (Withdrawn)]

15. (Original) A method according to claim 10 wherein said method further comprises adding said cells to donor stem cells prior to introduction into said patient.

[Claims 16-17 (Withdrawn)]

29. (Previously added) A method according to claim 2 wherein said PBMC are enriched for CD3+CD4-CD8- cells.

30. (Previously added) A method according to claim 10 wherein said PBMC are enriched for CD3+CD4-CD8- cells.

31. (Currently amended) A method for treating donor cells to ameliorate graft versus host disease in a recipient patient comprising:

- a) removing peripheral blood mononuclear cells (PBMC) from a donor;
- b) selectively enriching said PBMC for CD3+CD4-CD8- cells;

- c) treating said CD3+CD4-CD8- cells with a suppressive-inducing composition comprising TGF- β , and IL-2 and a T cell activator for a time sufficient to induce T cell tolerance in said patient; and
c) introducing said treated CD3+CD4-CD8- cells to said patient.

32. (Currently amended) A method for treating donor cells to ameliorate graft versus host disease in a recipient patient comprising:

- a) removing peripheral blood mononuclear cells (PBMC) from a donor;
b) selectively enriching said PBMC for CD3+CD4-CD8- cells;
c) treating said CD3+CD4-CD8- cells with a suppressive-inducing composition comprising TGF- β , IL-2 and a T cell activator for a time sufficient to generate suppressor cells; and
c) introducing said suppressor cells to said patient.

33. A method according to claim 2, 10, 31 and 32 – 4 wherein said T cell activator is anti-CD3.

Claims 34 –36 (Withdrawn)

[Claim 37 (Cancelled)]

Claims 38-40 (Withdrawn)

41. (New) A method for treating donor cells to ameliorate graft versus host disease in a recipient patient comprising:

- a) removing peripheral blood mononuclear cells (PBMC) from a donor;
b) selectively enriching said PBMC for CD3+CD4-CD8- cells;
c) treating said CD3+CD4-CD8- cells with a suppressive-inducing composition comprising TGF- β , IL-2 and the T cell activator anti-CD3 for a time sufficient to induce T cell tolerance in said patient; and
c) introducing said treated CD3+CD4-CD8- cells to said patient.

42. (New) A method for treating donor cells to ameliorate graft versus host disease in a recipient patient comprising:

- a) removing peripheral blood mononuclear cells (PBMC) from a donor;
b) selectively enriching said PBMC for CD3+CD4-CD8- cells;
c) treating said CD3+CD4-CD8- cells with a suppressive-inducing composition comprising TGF- β , IL-2 and the T cell activator anti-CD3 for a time sufficient to generate suppressor cells; and
c) introducing said suppressor cells to said patient.